目的 探讨虎地肠溶胶囊联合美沙拉嗪肠溶片治疗溃疡性结肠炎的临床疗效。方法 选取2017年4月-2019年4月在文昌市人民医院治疗的溃疡性结肠炎患者124例，根据用药的差别分为对照组（62例）和治疗组（62例）。对照组口服美沙拉嗪肠溶片，1 g/次，4次/d；治疗组在对照组基础上口服虎地肠溶胶囊，1.6 g/次，3次/d。两组患者均治疗2个月。观察两组患者临床疗效，同时比较治疗前后两组患者临床症候积分、DAI评分、Baron评分和IBDQ评分及炎症因子水平。结果 治疗后，对照组临床有效率为80.65%，显著低于治疗组的95.16%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者症候积分均显著降低（P<0.05），且治疗组患者临床症候积分明显低于对照组（P<0.05）。经治疗，两组患者DAI评分和Baron评分显著降低（P<0.05），IBDQ评分显著升高（P<0.05），且治疗组患者DAI评分、Baron评分和IBDQ评分明显好于对照组（P<0.05）。经治疗，两组患者血清白细胞介素-6（IL-6）、IL-17、肿瘤坏死因子-α（TNF-α）表达水平显著降低（P<0.05），IL-10和IL-13表达显著升高（P<0.05），且治疗组患者炎症因子水平明显好于对照组（P<0.05）。结论 虎地肠溶胶囊联合美沙拉嗪肠溶片治疗溃疡性结肠炎可有效改善患者临床症状，降低机体炎症反应，增强机体免疫功能，促进生活质量提高。

Objective To explore the clinical efficacy of Hudi Enteric-coated Capsules combined with mesalazine in treatment of ulcerative colitis. Methods Patients (124 cases) with ulcerative colitis in Wenchang People's Hospital from April 2017 to April 2019 were divided into control (62 cases) and treatment (62 cases) groups based on different treatments. Patients in the control group were po administered with Mesalazin Enteric-coated Tablets, 1 g/time, four times daily. Patients in the treatment group were po administered with Hudi Enteric-coated Capsules on the basis of the control group, 1.6 g/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacy was evaluated, and the clinical symptom scores, DAI, Baron and IBDQ scores, and the inflammatory factors levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 80.65%, which was significantly lower than 95.16% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the clinical symptom scores in two groups were significantly decreased (P<0.05), and which in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the DAI and Baron scores in two groups were significantly decreased (P<0.05), but IBDQ scores were significantly increased (P<0.05), and the DAI, Baron and IBDQ scores in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the serum IL-6, IL-17 and TNF-α levels in two groups were significantly decreased (P<0.05), IL-10 and IL-13 levels were significantly increased (P<0.05), and these inflammatory factors levels in the treatment group were significantly better than those in the control group (P<0.05). Conclusion Hudi Enteric-coated Capsules combined with mesalazine in treatment of ulcerative colitis can effectively improve the clinical symptoms, reduce inflammation, enhance immune function and improve the quality of life.

R975